A Phase 1 interventional study of CKD-381(formulation I) and CKD-381(formulation II) in GERD, sponsored by Chong Kun Dang Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-24.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 61st largest by enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 1, and was the 59th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
Chong Kun Dang Pharmaceutical has 9 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
A randomized, open-label, multiple-dose, and three-way cross over clinical trial to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)
Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)
Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
Drug: CKD-381(formulation I) · Drug: CKD-381(formulation II) · Drug: D026(Nexium 40mg)
1 tablet administered before the breakfast during 7 days
1 tablet administered before the breakfast during 7 days
1 tablet administered before the breakfast during 7 days
AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval at steady state)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
Cmax,ss(Maximum concentration of drug in plasma at steady state)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
Tmax,ss(Time to maximum plasma concentration at steady state)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
t1/2(Terminal elimination half-life)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
R(Accumulation ratio)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
CLss/F(Apparent Clearance at steady state)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
Vss/F(Apparent Volume of distribution at steady state)
Evaluation PK esomeprazole after multiple dose
Time frame: 0~24h
Cmax(Maximum concentration of drug in plasma)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
AUClast(Area under the plasma drug concentration-time curve from 0 to last)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
Tmax(Time to maximum plasma concentration)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
t1/2(Terminal elimination half-life)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
CL/F(Apparent clearance)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
Vd/F(Apparent volume of distribution)
Evaluation PK esomeprazole after single dose
Time frame: 0~24h
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in May 2018, 2 months.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 2 months is below that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CKD-381 · Esomeprazole
Chong Kun Dang Pharmaceutical →